Allo-SCT using unrelated donors is a curative treatment for patients with hematological disorders. The best donor is one matched for 10/10 HLA alleles, however studies have shown an additional survival benefit when considering other genetic factors. It has been shown that a six-nucleotide insertion/deletion polymorphism in the CASP8 gene promoter results in reduced susceptibility of T lymphocytes to undergo apoptosis. In 186 SCT recipients, we found a significantly better OS in those who received a transplant from a WT/WT donor compared with donors with a deletion (3 years: 52 vs 34%; P = 0.03; multivariate analysis; RR 0.61; 95% CI 0.38-0.98, P = 0.04). This was more marked when both the patient and the donor had a deletion (3 years OS: 62% compared with 36%, P = 0.01). As the majority of these patients received Alemtuzumab during conditioning, we went on to analyze the in vitro effect of the polymorphism on Alemtuzumab-induced apoptosis. We showed statistically significantly higher percentages of apoptotic naïve CD4 (P o 0.0005) and CD8 (P o 0.0005) T cells in WT/WT donors in comparison with donors with a deletion. These data imply an unrecognized role for the CASP8 promoter polymorphism on survival following unrelated SCT particularly in the context of T-cell depletion with Alemtuzumab.
INTRODUCTION
Allo-SCT is a curative treatment for many patients with hematological malignancies. The development of GVHD, and a subsequently increased TRM rate remains a major impediment to transplant success. 1 The anti-CD52 monoclonal Ab Campath-1H (Alemtuzumab) effectively depletes T lymphocytes and Agpresenting cells [2] [3] [4] and reduces the risk of both acute (aGVHD) and chronic GVHD (cGVHD). 5, 6 There are three main pathways that have been established in Alemtuzumab-mediated cell death: complement-dependent cytotoxicity, 7, 8 Ab-dependent cell mediated cytotoxicity 9, 10 and apoptosis (activation induced cell death, AICD). 11 One of the intracellular mechanisms resulting in apoptosis induced death by Alemtuzumab is via caspase activation. 12 Caspases are the prime executioners of the major apoptotic pathway and Caspase-8 is pivotal in initiating the series of caspase cascades after being stimulated by apoptotic signals generated by the interactions of the death receptor ligands. [12] [13] [14] In addition to their role in apoptosis, caspases are essential for the regulation of normal lymphocyte development, cell differentiation, inflammation and innate immunity. 15 In particular, caspase-8 has a broad role in regulating lymphocyte homeostasis, NF-KB activation and differentiation of monocytes to macrophages. 16 A six-nucleotide insertion/deletion variant (rs3834129, − 652 6Ndel AGTAAG) in the promoter of the CASP8 gene, which encodes the caspase-8 protein, has been associated with reduced susceptibility to multiple cancers, including non-Hodgkin's Lympoma, 17, 18 and it has been shown that the polymorphism has an effect on the susceptibility of T lymphocytes to undergo apoptosis. 19 This is due to the destruction of a binding site for the transcriptional activator SP1 and a consequent decrease in caspase-8 transcription. T lymphocytes from CASP8 − 652 6Ndel homozygous (del/del) and heterozygous wild-type (WT) and del-(WT/del) individuals showed reduced AICD rates upon stimulation with cancer cell Ags and resistance to apoptosis in an allele dose-dependent manner. 19 The conclusions drawn from these studies were that homozygotes for the − 652 6Ndel polymorphism are less susceptible to the development of cancer because of reduced AICD of T lymphocytes.
On the basis of these studies, we hypothesized that the CASP8 promoter − 652 6Ndel variant would affect outcome following unrelated donor SCT. The positive findings from this retrospective study, and the fact that in our cohort most transplants used Alemtuzumab as a means of GVHD prophylaxis, led us to perform functional in vitro studies to investigate the mechanisms underlying this observation.
MATERIALS AND METHODS

Patients and donors
Genotyping for the CASP8 promoter polymorphism was performed in 186 transplant recipients and their Anthony Nolan volunteer unrelated donors, who underwent an SCT for a hematological malignancy at 1 of 25 transplant centers in the United Kingdom between 1997 and 2006. These patients form a subset of a previous study that characterized their HLA types at high resolution for six HLA loci. Healthy volunteers for the functional studies were chosen for their CASP8 promoter polymorphism genotype (mean age = 31, range 21-58; 13 male and 8 female).
Ethical approval
Ethical approval was obtained from the National Research Ethics Service (NRES; www.nres.nhs.uk). Written informed consent for the study had been obtained from all recipients and their donors at the time of transplantation.
Genotyping of patients and healthy donors Donor and recipient genomic DNA was extracted from whole blood using the salting out technique. CASP8 − 652 6Ndel variant genotyping was performed by PCR followed by fragment size analysis or by PCR-SSP (PCR using sequence-specific primers).
Fragment size analysis
For fragment size analysis, a 177-bp fragment of the CASP8 promoter was amplified by using an FAM-labeled forward primer 5′-CTGCATGCCAG GAGCTAAGT-3′ and the reverse primer 5′-GCCATAGTAATTCTTGCTCTGC-3′. These primers have been previously described. 19 Single-round PCR amplification was performed using AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster City, CA, USA). Each reaction consisted of 10x Taq buffer, 25 mM MgCl 2 , 1 μM of reverse primer, 1 μM of forward primer, 1 unit of AmpliTaq Gold, 150 μM dNTP mix and approximately 100 ng of subject DNA. The final volume of 25 μL was made up with molecular grade sterile water. The cycling conditions for the PCR involved activation of Taq at 95°C for 10 min, followed by 27 cycles of denaturation stage at 95°C for 30 s, annealing at 60°C for 30 s and extension at 72°C for 30 s. This was followed by a final extension at 72°C for 2 min. Genotyping was carried out by a fragment analysis on ABI Prism 3130 Genetic Analyzer using the GeneMapper ID software v3.2 (Applied Biosystems).
PCR using sequence-specific primers A 222-bp fragment of the CASP8 WT allele was amplified by PCR using forward 5′-GGTCACGCAGCTAGTAAGTGG-3′ and reverse 5′-CCACAGGCTG TACAGGAAGC-3′ primers. The CASP8 del allele was amplified into a 162-bp fragment by using forward 5′-CTGCATGCCAGGAGCTAAG-3′ and reverse 5′-ATTCTTGCTCTGCCAAGC-3′ primers. A 351-/357-bp fragment covering the region of interest was amplified using forward 5′-CTGCATGCCAGGAGC TAAG-3′ and reverse 5′-CCACAGGCTGTACAGGAAGC-3′ primers. PCR-SSP amplification was carried out using BioTaq polymerase (Bioline, London, UK), 0.7 mM MgCl 2 , 12.5 pmol/μL of WT forward primer, 12.5 pmol/μL of control forward primer, 12.5 pmol/μL of control reverse primer, 25 pmol/μL of del reverse primer, 10 × NH 4 buffer, 0.4 mM of dNTP mix and 50 ng/mL of DNA. Molecular grade sterile water was added to make up a final volume of 25.5 μL. The cycling conditions for the PCR were as follows: 95°C for 5 min, followed by 40 cycles of denaturation stage at 95°C for 30 s, annealing at 63.8°C for 30 s, and extension at 72°C for 2 min, and a final extension at 72°C for 8 min. PCRs were carried out using a MJ Research PTC-200 Peltier Thermal Cycler (GMI Inc., Ramsey, MA, USA) and fragment size analysis was determined using agarose gel electrophoresis.
A proportion of the samples was sequenced to confirm their genotype and to ensure validity of the procedure. All genotyping results correlated with those obtained by sequencing.
Cell preparation and apoptosis assay
Mononuclear cells were isolated from heparinized PB by density-gradient centrifugation using lympholyte-H (VWR, Leicestershire, UK). T cells were activated for 48 h using 100 IU/mL of IL-2 (Prospec, Ness Ziona, Israel) and the T-cell activation/expansion kit (Miltenyi Biotec, Surrey, UK) as recommended by the manufacturer, however, a 1:1 loaded Anti-Biotin MACSiBead Particle to cell ratio was used to achieve optimal activation. ALEMTUZUMAB − 1H (Genzyme Corporation, Oxford, UK), 30 μg/mL, was a kind gift from Dr P Veys from Great Ormond Street Hospital, London, UK. Activated cells were treated with 0.1 μg/mL and 1.2 μg/mL of ALEMTUZU-MAB − 1 H. Cell viability was analyzed at 24 h after treatment with ALEMTUZUMAB − 1 H. Untreated cells were used as controls. Viability of the cells was assessed by flow cytometry and analyzed as apoptotic cells (Annexin V+7-AAD − ) and necrotic cells (Annexin V+7-AAD+).
Statistical methods
Data were compiled and maintained in SPSS. Analysis was performed using SPSS version 15.0 (SPSS Inc, Chicago, IL, USA) and R version 2.8.0 (http://www.r-project.org). Relapse was defined as any evidence of diseases reported to the registry whether hematological (all diseases), cytogenetic (CML/MDS), molecular (CML) or radiological (lymphoproliferative), although virtually all cases were hematological. DFS was defined as survival without ever suffering from disease relapse post transplant. The probabilities of OS and DFS were compared using log-rank statistics and calculated by the Kaplan-Meier method. The probabilities of TRM, disease relapse and cGVHD were compared using Gray's test and analyzed using the cumulative incidence method. Competing events included in the cumulative incidence analysis for TRM, disease relapse and cGVHD were relapse, death without relapse and death without cGVHD, respectively. The chi-squared test was used to analyze data on aGVHD and achievement of neutrophil engraftment. Multivariate analysis was performed using Coxregression analysis for time-dependent variables (OS, DFS and TRM) and Binary logistic regression analysis for aGVHD. Factors included in the multivariate model are recipient age and CMV serostatus of the recipient for OS and DFS, and recipient age, disease type and type of conditioning regimen in TRM. Factors included in the multivariate regression analysis for aGvHD were sex-matched transplants, degree of HLA matching, disease type, stage of disease at the time of SCT and the type of conditioning regimen. All other patient and donor factors found listed in Table 1 were not statistically significant. P-values of ⩽ 0.05 were considered significant, with those between 0.05 and 0.1 defined as a trend. All functional data were presented as mean ± s.d. values. For statistical analysis, the non-parametric t-test was used (Po0.05 was considered significant).
RESULTS
Clinical results
Patients. Patient and transplant characteristics are shown in Table 1 . Myeloablative conditioning was with TBI and CY. Reduced intensity conditioning was fludarabine based (either with melphalan or with BU). Eighty-five percent of recipients had T-cell depletion included in their pre-transplantation conditioning with in vivo or ex vivo ('Campath in the bag') Alemtuzumab (Alemtuzumab; Schering Health Care Ltd, West Sussex, UK). The median follow-up for surviving patients is 4 years.
CASP8 promoter polymorphism frequencies. The frequency of the three genotypes in the CASP8 promoter region was Recipients: WT/WT = 0.26, WT/del = 0.49, del/del = 0.24 and donors: WT/WT = 0.33, WT/del = 0.40, del/del = 0.25. The frequencies in both the donor and the recipient populations were in Hardy-Weinberg equilibrium (data not shown). As we were interested in the impact of the presence of a deletion variant in the donor genotype, we compared those patients who received a transplant from a WT donor and those from a donor with a CASP8 652 6N deletion polymorphism (del/WT or del/del). These two groups had no significant difference in any pre-transplant variable ( Table 1) .
Impact of donor CASP8 genotype on GVHD and TRM Acute GVHD was analyzed in 175 recipients with complete data for this variable. In all, 46.7% of recipients developed aGVHD, 25.7% grade II-IV.
We found a significant reduction in grade II-IV aGVHD in recipients receiving a graft from a WT/WT donor compared with those receiving a graft from donors with one or two deletions (17 vs 30%; P = 0.04). Other factors associated with an increase in aGvHD were HLA-mismatched transplants (40 vs 20%; P = 0.011) and sex-mismatched transplants (18 vs 36%; P = 0.03). In multivariate analysis, receiving a graft from a donor with a WT/WT CASP8 promoter genotype remained significantly associated with a reduction in aGVHD (HR 0.33; 95% confidence interval (CI) 0.13-0.80; P = 0.01). There was no significant impact of the donor CASP8 promoter genotype on the incidence of cGVHD.
The overall TRM was 28% (51/182) at 2 years. There was a significantly lower TRM at 2 years (30 vs 15%; P = 0.05; Figure 1 ) in those recipients who received a graft from WT/WT, as compared with the recipients who received a graft from donors with other genotypes. The only other factor that was found to be significant in the univariate analysis for TRM was recipient CMV-negative serostatus (P = 0.04). In multivariate analysis for TRM, receiving a graft from a WT/WT donor was associated with a trend toward lower TRM (HR 0.58; 95% CI, 0.30-1.11; P = 0.1). The causes of TRM were infection in 62%, GVHD in 15%, organ failure in 21% and graft failure in 2%. Lymphoproliferative disease/other includes: CLL (n = 4), Hodgkin's disease (n = 3), non-Hodgkins lymphoma (n = 11), myeloproliferative disease (n = 2) and plasma cells disorders (n = 10). Early: AML/ALL CR1, MDS, CML CP, myeloma VGPR; Late: AML/ALL CR2 or relapse, CML AP/BC, lymphoproliferative disease PR or relapse, myeloma relapse.
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Impact of CASP8 promoter genotypes on survival and relapse The median survival and DFS of the recipients were 4 (range o1 month to 9.4 years) and 3 years, respectively. The estimated 5-year OS was 52% in recipients who received a graft from a WT/WT donor compared with 34% in those who received a graft from a donor with a deletion (log-rank P = 0.032; Figure 2a) . DFS was 39% in the patients with a WT/WT donor compared with 18% in the group that received a graft from a donor with WT/del or del/del genotypes (log-rank P = 0.03; Figure 2b ). These effects remained statistically significant in multivariate analysis for OS (HR 0.61; 95% CI, 0.38-0.98; P = 0.04) and a trend for DFS (HR 0.69; 95% CI, 0.47-1.01; P = 0.06). There was no significant difference seen whether the patients received Alemtuzumab or not (data not shown).
The CASP8 promoter genotype in the recipient appeared to have no effect on either DFS or OS and neither the donor nor the recipient CASP8 promoter genotype had a significant impact on the incidence of relapse.
Interaction between donor and recipient genotypes To assess whether there was a cumulative effect of the polymorphism in both the patient and the donor, the cohort of 186 recipients was divided into two groups: (1) Recipients with at least one CASP8 deletion allele (that is, WT/del or del/del, n = 137) and (2) Recipients with WT/WT genotype, n = 49. In the group of recipients with a WT/WT genotype no significant impact of any donor genotype was seen in OS, DFS or TRM. However a striking impact of donor genotype was seen in the subgroup of recipients 0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 Recipients with graft from donors of del/del or WT/del. n = 120
Recipients with graft from donors of WT/WT. n = 62 Figure 1 . Impact of donor genotype on TRM.
Caspase-8 promoter polymorphism in transplantation BE Shaw et al where one or two deletions were present. The OS at three years was 62% in those who received a graft from a WT/WT donor compared with 36% in those who received a graft from other donors (log-rank P = 0.01; Figure 3a) . The DFS in this group was also significantly better at 54 vs 26% at 2 years (log-rank P = 0.003; Figure 3b ).
Functional studies
Viability of activated naïve T cells. We showed statistically significantly higher percentages of apoptosis in naïve CD4 T cells (60-70%) from WT/WT donors in comparison with donors with WT/del or del/del genotypes (10-22%) (P o0.0005). No difference was observed between the latter two groups (Figure 4a) . Similarly, Alemtuzumab induced 44-54% apoptosis in naïve CD8 T cells from WT/WT donors and 16-20% apoptosis in naïve CD8 T cells from WT/del or del/del donors (P o 0.0005) (Figure 4c ). No necrosis was observed in either of these cellular populations (Figures 4b and d) .
Viability of activated memory T cells. Higher levels of apoptosis were noted in memory CD4 T cells from WT/WT donors (65-70%) compared with WT/del (45-55%) and del/del genotypes (35-40%) (P o 0.0001) (Figure 5a ). Similarly, 62-68% apoptosis was detected in memory CD8 T cells from donors compared with WT/del (38-56%) and del/del genotypes (22-28%) (P o0.001) (Figure 5c ). Interestingly, apoptosis mediated by Alemtuzumab in memory T cells seemed to increase with additional copies of the deletion (Figure 5a and c) . As for naive T cells, no necrosis was observed in memory CD4 or CD8 T cells (Figures 5b and d) .
Viability of fresh activated NKT cells. Differences in the rates of apoptosis were noted in this subset, which was most marked in those with multiple copies of the deletion (P = 0.03).
Other cell subsets. No differences in the rates of apoptosis or necrosis were seen in either NK cells or Treg cells from either genotype.
DISCUSSION
The results presented here support our initial clinical hypothesis that the presence of a CASP8 deletion in donor cells would be associated with a worse patient outcome following unrelated donor transplant. We observed that using a donor with the CASP8 promoter deletion variant was associated with an increased risk of grade II-IV acute GVHD, with a subsequent increased risk of TRM resulting in a significantly reduced OS and DFS. The fact that the survival detriments were predominantly immune mediated (GVHD, infection), in an Alemtuzumab conditioning setting, led us to investigate directly the effect of Alemtuzumab on cellular subsets based on the donor genotype.
Our functional studies produced results entirely in keeping with this observation. Alemtuzumab induced significantly less apoptosis in naïve and memory CD4 and 8 T cells, as well as NKT cells in the presence of one or two copies of the CASP8 deletion. This suggests that the functional T-cell dose received by patients with a donor containing one or more deletion is higher and thus the risk of GVHD increased. T lymphocytes from CASP8 deleted individuals have been shown to result in reduced AICD rates upon stimulation. In one study, it was reported that the rate of apoptosis was reduced in an allele dose-dependent manner. 4 Although we did not find this to be the case with the donors in our study, there was some suggestion, from the functional studies, that an allele dose effect may be present in some cellular subsets (for example, NKT cells). Additionally, where both the patient and the donor had an 'apoptosis-resistant' genotype the OS was significantly worse, suggesting that assessment for the presence of multiple deletions may be relevant.
Previously, homozygotes and heterozygotes for this deletion variant were found to have lower caspase-8 expression and activity in response to anti-FAS, which was shown to be due to the destruction of a binding site for the transcriptional activator SP1. 19 The decrease in caspase-8 activity was dependent on the number of deletions present (less activity in homozygotes compared to heterozygotes). In our study, the levels of luminescence were comparable among the three CASP8 genotypes (performed by comparing the level of relative luminescence units by using a homogenous luminescent assay consisting of thermostable luciferase, data not shown). This discrepancy may be due to the fact that our experimental design used PBMC from healthy donors, while that by Sun et al. 19 was carried out using PBMC from cancer patients where the ratio of CD25+ CD4+ cells to CD3+ cells (T cells) was significantly higher than that from healthy donors. Thus, the environment in which these effects occur may be of critical importance and multiple influences may impact in the complex post-transplant milieu.
While these results have obvious biological relevance, they also potentially have an impact on the choice of donor. The main requirement for selection of an unrelated donor is well recognized to be one who is a match at 10/10 (or 8/8) HLA alleles. 20, 21 Selecting a donor based on secondary selection donor characteristics, such as donor age 22 or other (non-classic HLA) genetic factors, [23] [24] [25] can further enhance outcomes. There are certain limitations to this study due to the data being registry based. There is variation in the disease and transplant characteristics and Alemtuzumab doses were not available for all of the patients. Additionally, it would have been highly desirable to analyze lymphocyte subsets in recovering immune system of the patient. Functional studies (such as enumerating CMV directed T cells or assessing CMV reactivations) would be very desirable in future validation studies, however this information is not requested on routine forms.
Here, we have shown that CASP8 polymorphisms in the donor have a clear impact on patient outcome, suggesting that outcomes could be enhanced by avoiding those donors carrying the deletion. The in vitro studies we performed suggest that this effect may be mediated by reduced susceptibility to apoptosis when T cells, and other subsets, carrying the deletion are exposed to Alemtuzumab. These clinical findings may be specifically relevant to transplant recipients who receive Alemtuzumab as a component of their conditioning, however, given the broad role of Caspases, it is possible that similar effects may be seen in transplant patients treated with other regimens and GVHD prophylaxis including anti-thymocyte globulin. T cells. ***P o0.0005 (n = 7 each group). ***Po0.0005, **P o0.005, and *P o0.05 (n = 7 each group).
